Triple Agonist Stack – Retatrutide + Cagrilintide

Description

Triple Agonist Stack combines Retatrutide (GLP-1/GIP/glucagon triple agonist) with Cagrilintide (long-acting amylin analogue) for paired investigation of incretin and amylin signalling.

Mechanism: Retatrutide drives the incretin-glucagon axis while Cagrilintide engages amylin receptors and calcitonin receptor isoforms, producing complementary satiety and gastric-emptying effects via independent pathways.

Research findings: Combination amylin-incretin protocols are an active research area. Pre-clinical data suggests additive weight-loss effects relative to either monotherapy and improved tolerability profiles via slower titration. Use under documented research protocol only.

Handling: Lyophilized peptide. Store sealed at -20°C for long-term stability or 2-8°C short-term. Reconstitute with bacteriostatic water or 0.6% acetic acid as appropriate to the molecule.

For research purposes only. Not for human consumption. This material is intended exclusively for in-vitro laboratory and preclinical research applications conducted by qualified personnel.